retatrutide farts Eli Lilly infiltrates anti-obesity market as Phase III trial for begins Retatrutide is a game changer.

But rapid fat reduction often comes with side effects: skin laxity, facial hollowing, and volume loss

Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks

Once all the tubes are filled, they can then be placed into the DuoQuattro Centrifuge

(PubMed) Bernhard W, Shunova A, Machann J, et al

Thereafter, mice were divided into two groups ( n = 6/group) and started on one of two treatments: a control diet (Con) and HFD